Live Breaking News & Updates on Lysine Demethylase

Stay updated with breaking news from Lysine demethylase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tachyon Presents Preclinical Data on the Company's Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

HOUSTON (BUSINESS WIRE) Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research. ....

United States , Frank Perabo , American Association For Cancer Research , Ernestn Morial Convention Center , Tachyon Therapeutics Inc , Tachyon Therapeutics , American Association , Cancer Research , Annual Meeting , Convention Center , New Orleans , First In Class Inhibitor , Lysine Demethylase , Diffuse Largeb Cell Lymphoma , Chromatin Modifiers ,

New epigenetic regulatory mechanisms involved in multiple myeloma growth

An international team of researchers has analyzed the function of the histone demethylase KDM5A in multiple myeloma, one of the three major hematological cancers, and clarified the mechanism by which it promotes myeloma cell proliferation. They also developed a novel KDM5 inhibitor and showed that it inhibits cancer cell growth in a myeloma mouse model. The researchers expect that new therapies targeting KDM5A will be developed in the future. ....

United Kingdom , Hiroto Ohguchi , Kumamoto University , Dana Farber Cancer Institute , Associate Professor Hiroto Ohguchi , Blood Cancer Discovery , Lysine Demethylase , Medicine Health , Pharmaceutical Chemistry , ஒன்றுபட்டது கிஂக்டம் , குமாமோடோ பல்கலைக்கழகம் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , இரத்தம் புற்றுநோய் கண்டுபிடிப்பு , உயிர் வேதியியல் ,